NASDAQ · Biotechnology

IMMX (IMMX) Stock

$8.55 +4.65% NASDAQ: IMMX Healthcare

Valuation

MetricValue
Price$8.55
Market Cap$465.14M
P/E Ratio-9.96
P/B Ratio5.13
P/S Ratio0.00
EPS (TTM)$-0.89
52-Week High$12.02
52-Week Low$1.94
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-30.85%
ROA-27.62%
ROCE-28.72%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio10.10

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-1.0M$-8.0M$-16.0M$-23.0M$-27.0M
Net Profit$-24.0M$-8.0M$-15.0M$-22.0M$-29.0M
EPS$-6.64$-0.59$-0.89$-0.76$-0.89
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$18.0M$15.0M$20.0M$23.0M$105.0M
Total Liabilities$0$2.0M$4.0M$10.0M$11.0M
Cash$18.0M$13.0M$18.0M$18.0M$94.0M
Borrowings$0$0$0$1.0M$1.0M

Latest News

Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet Zacks · Jun 18, 2026 BofA Initiates Immix Biopharma at Buy With $27 Price Target MT Newswires · Jun 18, 2026 Exploring 3 High Growth Tech Stocks in the US Market Simply Wall St. · Jun 9, 2026 Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High? Zacks · May 27, 2026 Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock GlobeNewswire · May 22, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-7.0M$-11.0M$-15.0M$-24.0M
Investing Cash Flow$0$0$0$-2.0M$-8.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$17.0M$-4.0M$4.0M$0$76.0M
Free Cash Flow$-2.0M$-7.0M$-11.0M$-16.0M$-25.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-6.90%
Quick Ratio8.76
Interest Coverage—
Return 1Y203.45%
Return 3Y325.12%
Return 5Y—

Ownership

Insiders Held17.56%
Institutions Held45.30%
Institutions Float Held54.95%
Institutional HolderSharesReport Date
Janus Henderson Group PLC4,802,0022026-03-31
Saturn V Capital Management LP3,693,5852026-03-31
Eventide Asset Management LLC2,549,0192026-03-31
Vanguard Capital Management LLC1,787,9942026-03-31
Millennium Management Llc1,750,2002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATOS $2.36 -2.48% -1.23 $23.54M 0.00%
COYA $4.00 -6.21% -2.62 $72.84M 0.00%
MGNX $3.78 +3.00% -2.92 $240.27M 0.00%
ONCYOncolytics Biotech Inc. $0.81 -0.78% -3.40 $80.88M 0.00%
ORMP $4.39 +7.86% 2.85 $179.67M 5.84%

About IMMX

IMMX is led by CEO Ilya Rachman, employs 18 people, headquartered in US, publicly traded since 2021.

IMMX stock trades at $8.55 with a market capitalization of $465.14M. The stock is valued at a price-to-earnings (P/E) ratio of -9.96, price-to-book of 5.13, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.94 and $12.02, and currently trades 28.9% below its 52-week high.

On profitability, IMMX generates a return on equity (ROE) of -30.85%, return on capital employed of -28.72%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides